Company
Kaleo INC
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
4
1 still marketed
Novel approvals
0
Approvals since 2021
1
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Naloxone Hydrochloride (Autoinjector) approved Priority reviewFeb 28, 2022
- Auvi-Q new use Priority reviewNov 17, 2017
- Evzio (Autoinjector) approved Priority reviewOct 19, 2016
- Evzio approved Priority reviewApr 3, 2014
- Auvi-Q approved Aug 10, 2012
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (1)
Newest FDA action first.
- Auvi-Q Epinephrine · 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.